IP Library Granted Patent US 7,776,845
Granted Patent B2
US 7,776,845 · App. 11/835,334 · Granted Aug 17, 2010

Pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,776,845
App. No.
11/835,334
Granted
Aug 17, 2010
Kind
B2
Abstract

The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.

Claims (35)

1. A compound having the structure

wherein,

one of R 5 and R 6 is —OH and the other R 5 and R 6 is —H;

one of R 12 and R 13 is —OH and the other R 12 and R 13 is —H;

R 14 and R 15 are —H;

R 16 is —H;

R 17 is —H or —OH;

R 18 is —OH;

R 19 is ethynyl; and

R 24 and R 25 are —CH 3 .

2. The compound of claim 1 having the structure

3. The compound of claim 1 having the structure

4. The compound of claim 1 having the structure

5. The compound of claim 1 having the structure

6. The compound of claim 1 having the structure

7. The compound of claim 1 having the structure

8. The compound of claim 1 having the structure

9. The compound of claim 1 having the structure

10. The compound of claim 1 having the structure

11. A pharmaceutical formulation comprising one or more excipients and a compound having the structure

wherein,

one of R 5 and R 6 is —OH and the other R 5 and R 6 is —H;

one of R 12 and R 13 is —OH and the other R 12 and R 13 is —H;

R 14 and R 15 are —H;

R 16 is —H;

R 17 is —H or —OH;

R 18 is —OH;

R 19 is ethynyl; and

R 24 and R 25 are —CH 3 .

12. The pharmaceutical formulation of claim 11 having the structure

13. The pharmaceutical formulation of claim 12 wherein the pharmaceutical formulation is for parenteral administration.

14. The pharmaceutical formulation of claim 12 wherein the pharmaceutical formulation is for oral administration.

15. The pharmaceutical formulation of claim 14 wherein the pharmaceutical formulation is in the form of unit dosages, optionally capsules, cachets or tablets.

16. The pharmaceutical formulation of claim 12 wherein the pharmaceutical formulation is for topical, buccal or sublingual administration.

17. The pharmaceutical formulation of claim 12 wherein the pharmaceutical formulation is for aerosol administration.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2015
From: RESERVA LLC
To: NEURMEDIX, INC.
Reel/Frame 035030/0541 →
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →
CHANGE OF NAME Recorded Mar 3, 2010
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024024/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2007
From: FRINCKE, JAMES M; LARDY, HENRY; MARWAH, PADMA
To: HOLLIS-EDEN PHARMACEUTICALS, INC.
Reel/Frame 019681/0090 →